These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6775530)

  • 21. Presence of activator proteins for the enzymatic degradation of glucosylceramide in several human tissues.
    Vaccaro AM; Ciaffoni F; Mandara I; Suzuki K
    Clin Chim Acta; 1988 Mar; 172(2-3):323-34. PubMed ID: 3370844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.
    Motabar O; Goldin E; Leister W; Liu K; Southall N; Huang W; Marugan JJ; Sidransky E; Zheng W
    Anal Bioanal Chem; 2012 Jan; 402(2):731-9. PubMed ID: 22033823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of membrane-bound glucosylceramide: beta-glucosidase in fibroblasts cultured from normal and glucosylceramidotic human skin.
    Mueller OT; Rosenberg A
    J Biol Chem; 1979 May; 254(9):3521-5. PubMed ID: 429368
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.
    Meivar-Levy I; Horowitz M; Futerman AH
    Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):377-82. PubMed ID: 7980395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocerebroside storage in normal monocyte cultures.
    Hardy B; Teitelman-Weissman B; Chazan S; Neri A
    Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Properties of beta-glucosidase in cultured skin fibroblasts from controls and patients with Gaucher disease.
    Turner BM; Hirschhorn K
    Am J Hum Genet; 1978 Jul; 30(4):346-58. PubMed ID: 102189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease.
    Aerts JM; Donker-Koopman WE; Koot M; Barranger JA; Tager JM; Schram AW
    Clin Chim Acta; 1986 Jul; 158(2):155-63. PubMed ID: 2943536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.
    Burke DG; Rahim AA; Waddington SN; Karlsson S; Enquist I; Bhatia K; Mehta A; Vellodi A; Heales S
    J Inherit Metab Dis; 2013 Sep; 36(5):869-72. PubMed ID: 23151684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infantile Gaucher's disease: glucocerebrosidase deficiency in peripheral blood leukocytes and cultured fibroblasts.
    Sengers RC; Lamers KJ; Bakkeren JA; Schretlen ED; Trijbels JM
    Neuropadiatrie; 1975 Nov; 6(4):377-82. PubMed ID: 241947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.
    Fabbro D; Desnick RJ; Grabowski GA
    Am J Hum Genet; 1987 Jan; 40(1):15-31. PubMed ID: 3812484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.
    Aerts JM; Donker-Koopman WE; Brul S; Van Weely S; Sa Miranda MC; Barranger JA; Tager JM; Schram AW
    Biochem J; 1990 Jul; 269(1):93-100. PubMed ID: 2198026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble and membranous neutral beta-glucosidases.
    Ben-Yoseph Y; Nadler HL
    Prog Clin Biol Res; 1982; 95():465-80. PubMed ID: 6812082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gaucher type I (Ashkenazi) disease: a new method for heterozygote detection using a novel fluorescent natural substrate.
    Grabowski GA; Dinur T; Gatt S; Desnick RJ
    Clin Chim Acta; 1982 Sep; 124(1):123-35. PubMed ID: 6889929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assay of the beta-glucosidase activity with natural labelled and artificial substrates in leukocytes from homozygotes and heterozygotes with the Norrbottnian type (Type 3) of Gaucher disease.
    Svennerholm L; Håkansson G; Dreborg S
    Clin Chim Acta; 1980 Sep; 106(2):183-93. PubMed ID: 6773705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gaucher's disease II. Studies on the kinetics of beta-glucosidase and the effects of sodium taurocholate in normal and Gaucher tissues.
    Choy FY; Davidson RG
    Pediatr Res; 1980 Jan; 14(1):54-9. PubMed ID: 6767218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple glycosidase deficiencies in a case of juvenile (type 3) Gaucher disease.
    Chiao YB; Hoyson GM; Peters SP; Lee RE; Diven W; Murphy JV; Glew RH
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2448-52. PubMed ID: 27787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors and stimulators of glucocerebroside metabolism.
    Radin NS
    Prog Clin Biol Res; 1982; 95():357-83. PubMed ID: 6214799
    [No Abstract]   [Full Text] [Related]  

  • 38. Gaucher disease: isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue.
    Pentchev PG; Brady RO; Blair HE; Britton DE; Sorrell SH
    Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3970-3. PubMed ID: 29293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.
    van Weely S; van den Berg M; Barranger JA; Sa Miranda MC; Tager JM; Aerts JM
    J Clin Invest; 1993 Mar; 91(3):1167-75. PubMed ID: 8450045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-reacting material in Gaucher disease fibroblasts.
    Beutler E; Kuhl W; Sorge J
    Proc Natl Acad Sci U S A; 1984 Oct; 81(20):6506-10. PubMed ID: 6593712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.